Oct. 9 at 5:59 PM
$CRVO "Together with other insights gained from Phase 2b, these results have enabled us to refine and optimize the design of our planned Phase 3 trial as we await FDA feedback later this quarter."
https://www.neurologylive.com/view/neflamapimod-advances-phase-3-trial-dementia-with-lewy-bodies-after-positive-rewind-lb-results